Adaptive Biotechnologies Corporation (ADPT) — DCF ValuationDiscounted Cash Flow intrinsic value with Bear, Base & Bull scenarios
Adaptive Biotechnologies Corporation (ADPT)
Revenue ($253M) below $1B threshold — insufficient business scale for DCF.
Alternative Approach:
Use EV/Sales vs. industry peers for growth-stage companies.
Insufficient data to compute DCF valuation for ADPT. This typically occurs with negative FCF, early-stage companies, or financials where standard DCF models require modification.
Unable to calculate intrinsic value. DCF requires positive free cash flow and complete financial data. For banks/REITs, we substitute Net Income or FFO respectively.
Standard two-stage DCF with 5-year explicit forecast period and Gordon Growth terminal value. WACC estimated from sector averages and company beta. For ADPT, insufficient data prevents full calculation—typically requires 3+ years of positive FCF history.